Development asset linked to Biodexa Pharmaceuticals in public FDA and regional records.
pharma · Familial adenomatous polyposis (FAP) · Familial Adenomatous Polyposis · BDRX
Biodexa Pharmaceuticals
Biodexa Pharmaceuticals Plc
Biodexa Pharmaceuticals drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
cardiff, GB HQ
2000 Founded
25 Employees
Public company Type
BDRX · NYSE Ticker
Company details
- Status
- Public
- HQ
- cardiff, GB
- Founded
- 2000
- Employees
- 25
- Programs
- 4
- Drugs
- 5
- Patents
- 2
Biodexa Pharmaceuticals pipeline
Portfolio lens on 5 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Biodexa Pharmaceuticals drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
Development asset linked to Biodexa Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Biodexa Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Biodexa Pharmaceuticals in public FDA and regional records. Mechanism: Voltage-gated L-type calcium channel blocker.
- Mechanism
- Voltage-gated L-type calcium channel blocker